Jean Paul Medina Carrion
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (15)
Year:
2025
Year:
2025
Background and purpose Thalamic alterations have been reported as a major feature in presymptomatic and symptomatic patients carrying the C9orf72 mutation across the frontotemporal dementia–amyotrophic lateral sclerosis (ALS) spectrum. Specifically, the pulvinar, a high‐order thalamic nucleus and timekeeper for large‐scale cortical networks, has been hypothesized to be involved in C9orf72 ‐related neurodegenerative diseases. We investigated whether pulvinar volume can be useful for differential diagnosis in ALS C9orf72 mutation carriers and noncarriers and how underlying functional connectivity changes affect this region. Methods We studied 19 ALS C9orf72 mutation carriers ( ALSC9+ ) accurately matched with wild‐type ALS ( ALSC9 −) and ALS mimic ( ALSmimic ) patients using structural and resting‐state functional magnetic resonance imaging data. Pulvinar volume was computed using automatic segmentation. Seed‐to‐voxel functional connectivity analyses were performed using seeds from a pulvinar functional parcellation. Results Pulvinar structural integrity had high discriminative values for ALSC9+ patients compared to ALSmimic (area under the curve [AUC] = 0.86) and ALSC9 − (AUC = 0.77) patients, yielding a volume cutpoint of approximately 0.23%. Compared to ALSmimic , ALSC9 − showed increased anterior, inferior, and lateral pulvinar connections with bilateral occipital–temporal–parietal regions, whereas ALSC9+ showed no differences. ALSC9+ patients when compared to ALSC9 − patients showed reduced pulvinar–occipital connectivity for anterior and inferior pulvinar seeds. Conclusions Pulvinar volume could be a differential biomarker closely related to the C9orf72 mutation. A pulvinar–cortical circuit dysfunction might play a critical role in disease progression and development, in both the genetic phenotype and ALS wild‐type patients.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Collaborators (14)
Eleonora Dalla Bella
Fondazione IRCCS Istituto Neurologico Carlo Besta
Alberto Redolfi
Head of Laboratory
-
Mario Stanziano
Fondazione IRCCS Istituto Neurologico Carlo Besta
Sara Palermo
Associate Professor
University of Turin
Cristina Moglia
-
luca giani
Istituti Clinici Scientifici Maugeri SpA IRCCS Lumezzane
Davide Fedeli
Istituto Neurologico Carlo Besta
Nicola CANESSA
Associate professor M-PSI/02
Istituto Universitario di Studi Superiori IUSS
John‐Paul Taylor
-
francesco ghielmetti
Fondazione IRCCS Istituto Neurologico Carlo Besta
Federica Agosta
-
matilde leonardi
Fondazione IRCCS Istituto Neurologico Carlo Besta
GIOVANNI SAVINI
Humanitas University
monica consonni
Fondazione IRCCS Istituto Neurologico Carlo Besta
Make your next move.
Prepare your application
Review drafts before you send them.